ReviewCurrent genetics2019
Yeast genetic interaction screens in the age of CRISPR/Cas.
Review in Current genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Synthetic lethal gene pairs: Experimental approaches and predictive models.Frontiers in genetics · 2022Pooled it
- EditingBiomolecules · 2026Review
- A temperature-sensitive mutant screen reveals a translational stress-induced cell-cycle arrest in a thermophilic archaeon.Molecular biology of the cell · 2025Article
- Combining Oligo Pools and Golden Gate Cloning to Create Protein Variant Libraries or Guide RNA Libraries for CRISPR Applications.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Simplicity within biological complexity.Bioinformatics advances · 2025Article
- CRI-SPA: a high-throughput method for systematic genetic editing of yeast libraries.Nucleic acids research · 2023Article
- A DNA assembly toolkit to unlock the CRISPR/Cas9 potential for metabolic engineering.Communications biology · 2023Article
- Improving therapeutic protein secretion in the probiotic yeast Saccharomyces boulardii using a multifactorial engineering approach.Microbial cell factories · 2023Article
- A DNA assembly toolkit to unlock the CRISPR/Cas9 potential for metabolic engineering.Research square · 2023Article
- Bridging Glycomics and Genomics: New Uses of Functional Genetics in the Study of Cellular Glycosylation.Frontiers in molecular biosciences · 2022Review
- Applications of CRISPR/Cas gene-editing technology in yeast and fungi.Archives of microbiology · 2021Article
- Systematic High-Content Screening of Fluorescently Tagged Yeast Double Mutant Strains.Methods in molecular biology (Clifton, N.J.) · 2021Article
- A self-consistent probabilistic formulation for inference of interactions.Scientific reports · 2020Article
- Next Generation Winemakers: Genetic Engineering inBioengineering (Basel, Switzerland) · 2020Review
- How yeast cells deal with stalled replication forks.Current genetics · 2020Review
- Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.Journal of hematology & oncology · 2020Review
- A glance at genome editing with CRISPR-Cas9 technology.Current genetics · 2020Review
- Genetic interactions derived from high-throughput phenotyping of 6589 yeast cell cycle mutants.NPJ systems biology and applications · 2020Article
- CATS: Cas9-assisted tag switching. A high-throughput method for exchanging genomic peptide tags in yeast.BMC genomics · 2020Article
- The CRISPR toolbox in medical mycology: State of the art and perspectives.PLoS pathogens · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The ease of performing both forward and reverse genetics in Saccharomyces cerevisiae, along with its stable haploid state and short generation times, has made this budding yeast the consummate model eukaryote for genetics. The major advantage of using budding yeast for reverse genetics is this organism's highly efficient homology-directed repair, allowing for precise genome editing simply by introducing DNA with homology to the chromosomal target. Although plasmid- and PCR-based genome editing tools are quite efficient, they depend on rare spontaneous DNA breaks near the target sequence. Consequently, they can generate only one genomic edit at a time, and the edit must be associated with a selectable marker. However, CRISPR/Cas technology is efficient enough to permit markerless and multiplexed edits in a single step. These features have made CRISPR/Cas popular for yeast strain engineering in synthetic biology and metabolic engineering applications, but it has not been widely employed for genetic screens. In this review, we critically examine different methods to generate multi-mutant strains in systematic genetic interaction screens and discuss the potential of CRISPR/Cas to supplement or improve on these methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.